🔗 Share this article

An underground economy for unapproved slimming medications is being driven by social media fitness personalities and vendors on communication apps, according to new investigations.

Investigational Drug Acquiring Traction Via Social Media

Retatrutide, which remains in clinical trials, is being promoted by social media influencers for its alleged weight-reducing effects. Followers are encouraged to contact these profiles privately for supplier links, while also receiving discount codes.

Active Trade on Social Networks

Additionally, a flourishing trade exists on messaging services, where groups with numerous of participants share “before and after” images, administration instructions and claims of next-day UK delivery. Vendors market the substance there before redirecting customers to other platforms for transactions.

Learning About The Experimental Drug

Retatrutide is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.

Healthcare Experts Express Concerns

Nevertheless, doctors and chemists have cautions that the sale of what is still an unlicensed medication in the UK is a cause for concern and could lead to users administering substances of uncertain source.

Several experts said the popularity for the experimental drug could be connected to the increasing price of approved slimming products such as Mounjaro.

Regulatory Status and Implementation

Marketing the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved drug that must not be promoted or supplied for personal consumption under the British medical regulations.

Some content creators attempt to sidestep the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but promotion and supply can still violate pharmaceutical, advertising, and consumer laws, risking penalties, legal action or imprisonment.

Platform Response and Content Removal

According to TikTok, the platform has taken down violative content and prohibited related hashtags and query recommendations. The organization stated it was committed to maintaining the service secure and investing in strengthening compliance measures.

Online Trading Activities

Research also discovered communities with up to 9,000 participants marketing the experimental drug using Telegram's built-in discovery tool, which functions like a online catalog. Typing “retatrutide” immediately displays groups with thousands of users, filled with images of weight loss, positive reviews and detailed guides for mixing or administering at residence.

Within moments of entering one community, a vendor shared WhatsApp details, where the majority of purchases take place. The vendor provided an instruction manual and guaranteed delivery within two days. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. None asked about weight, health issues or previous experience.

Item Information and Pricing

Within these groups, messages display dark colored packages with Royal Mail stickers, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at home with sterile water, or pre-filled injectors typically priced at £160 for 20 milligrams. When questioned how long a pen should be used, sellers give conflicting answers varying between a few weeks to “depends on your body”.

Platform Oversight and Security Actions

A spokesperson for the messaging service said it actively monitored dangerous content on its platform including content that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are injecting substances they cannot confirm. Although the science behind retatrutide is sound, these digital products may not include what they advertise,” said a pharmacy expert, the director of pharmacy at Chemist4U.

A medical professional of an online medical service connected the surge in interest to recent cost increases for authorized weight-loss drugs such as Mounjaro. “With prices increasing, patients are turning to social media. But counterfeit injections are highly risky. You cannot know what’s inside or whether the environment they were produced in was clean,” she said.

Her team has previously encountered individuals harmed by personal administration from unverified sources. “We recognize the frustration, but buying from messaging apps or communication platforms is taking chances with your health,” said Wyllie. “These materials could be impure or improperly measured.”

Producer Position

A representative from Eli Lilly stated retatrutide was in third stage research studies and had not been reviewed or authorized by any regulatory agency globally. “Consequently at this time no one can market [it] for human use,” they said, adding that any item “misleadingly claiming itself as a Lilly experimental substance not yet approved … may expose users to potentially serious health risks”.